Nearly half of the people with amyotrophic lateral sclerosis (ALS) treated with masitinib in a clinical trial survived…
Articles by Marisa Horak, MS
Long-term exposure to air pollution is not associated with an altered, or increased, risk of amyotrophic lateral sclerosis (ALS).
As part of preparations for a Phase 3 clinical trial to test its experimental therapy, masitinib, in people with amyotrophic…
It’s well established that some cases of amyotrophic lateral sclerosis (ALS) are caused by mutations that are inherited from…
A protein called UBQLN2 is key for regulating both proteins and fat molecules in nerve cells, and disruptions in these…
Two blood markers indicative of inflammation and cellular stress may help predict disease progression patterns and survival in people with…
Advocates and lawmakers are racing against a looming September deadline to prevent a “funding cliff” for critical amyotrophic lateral…
People living with amyotrophic lateral sclerosis (ALS) in the U.S. generally prefer care models where they can see multiple…
Early treatment with AL-S Pharma‘s infusion therapy AP-101 significantly extended survival and delayed the need for respiratory support…
An analysis of how polarized light interacts with clumps of proteins in the eyes may help differentiate amyotrophic lateral…